Cinnamon for Health & Longevity - Quick Reference Sheet

Cinnamon for Health & Longevity

Created on 09/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A cheap spice with a small but repeatedly measured effect on blood sugar, blood pressure, triglycerides and body weight — clearest where readings are already elevated, barely present where they are not. Easily swamped by sleep, food quality and training. The cheap supermarket type (cassia) stresses the liver; ground cinnamon repeatedly carries lead. Type and supplier matter more than amount. (Full Review)

Protocol

Standard dose
2 g/day
Trials used 1–6 g/day of ground bark. Glycemic and blood-pressure benefit concentrated at 2 g/day or less; weight effects needed 3 g/day or more.
Whole powder approach
Ground bark, capsules or stirred into food
Cheapest, and the form most positive trials used. The standardized aqueous extract, 250 mg twice daily, excludes coumarin. Neither is the default.
Timing
With meals
Ideally the largest carbohydrate-containing meal, split across two or three meals as the trials did. No trial supports morning or evening dosing.
Time to effect
Post-meal glucose rise
Immediate
Blunting occurs within a single meal.
Fasting glucose, hemoglobin A1c, lipids, weight
8–12 weeks
The interval required in the trials that found these changes.
Evaluation window
12 weeks minimum
The minimum honest window before judging effect.

Benefits

Contraindications
  • Chronic liver disease at Child-Pugh Class B or C, or any active hepatitis
  • Alanine aminotransferase or aspartate aminotransferase above three times the upper limit of normal
  • Pregnancy and lactation, at any dose above culinary use
  • Documented cinnamaldehyde or balsam-of-Peru contact allergy
  • Children under 12, for supplement-strength doses
  • Within two weeks of elective surgery
Key Interactions
  • Glucose-lowering prescription drugs: insulin, sulfonylureas (glipizide)
  • Liver-stressing prescription drugs: statins (atorvastatin), methotrexate, isoniazid, amiodarone
  • Antihypertensive prescription drugs: ACE inhibitors (lisinopril), ARBs (losartan), diuretics
  • Anticoagulants and antiplatelets: warfarin, apixaban, clopidogrel (theoretical only)
  • Over-the-counter medications: acetaminophen at or above 3 g/day, high-dose NSAIDs (ibuprofen)
  • Supplement interactions: berberine, chromium, alpha-lipoic acid, fenugreek, gymnema
  • Additive-effect supplements: dietary nitrate, magnesium, potassium, hibiscus, omega-3
  • Liver-loading supplements: green tea extract, kava, comfrey, high-dose niacin
  • Other intervention interactions: ketogenic diets, prolonged fasting, GLP-1 agonists

Risk & Side Effects

  • High: Coumarin-associated liver injury from cassia cinnamon; gastrointestinal upset
  • Medium: Allergic and oral mucosal reactions; lead contamination of cinnamon products
  • Low: Additive hypoglycemia with glucose-lowering medication; additive blood-pressure lowering with antihypertensive medication
  • Speculative: Reproductive and developmental toxicity; bleeding risk attributed to coumarin

Monitoring

Marker Target Why
Fasting glucose 75–86 mg/dL Primary efficacy endpoint
Hemoglobin A1c 4.8–5.2% Three-month average; filters daily noise
Fasting insulin 2–5 µIU/mL Detects insulin resistance before glucose rises
Alanine aminotransferase 10–19 U/L (women), 10–26 U/L (men) Safety endpoint for coumarin exposure
Triglycerides Below 80 mg/dL The lipid fraction moved most reliably
LDL cholesterol Below 100 mg/dL, particle count preferred Secondary lipid endpoint; response inconsistent
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammatory signal
Blood pressure Below 120/80 mmHg Efficacy endpoint and hypotension check
Blood lead Below 1.0 µg/dL Contamination check for daily users

Cadence: Baseline, then glucose, lipids, liver enzymes and blood pressure at 12 weeks, then every six to twelve months. Insulin or sulfonylurea users self-test glucose more often for the first two weeks.

Qualitative Assessment

  • Post-meal energy stability, particularly the absence of a mid-afternoon slump
  • Carbohydrate and sweet-food craving intensity
  • Digestive tolerance: nausea, heartburn, stool frequency, bloating in the first fortnight
  • Oral and perioral symptoms: burning, tingling, mucosal patches or lip swelling, each a discontinuation signal
  • Cognitive clarity and subjective memory, given unsettled human cognition evidence
  • For menstrual-pain use, pain intensity and duration across two consecutive cycles